Kenneth Peters, MD

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Kenneth Peters, MD sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).

14 total trials none currently recruiting 11 completed early-phase tilt top decile by trial count

Kenneth Peters, MD: 14 sponsored US clinical trials, none currently recruiting.

Kenneth Peters, MD sponsors 14 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Vulvodynia, with 1 trials.

Top-decile sponsor footprint

Kenneth Peters, MD ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 36/100

11 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

14 total, page 1 of 1

COMPLETED NA

Utilization of the BIOWAVE Device to Treat Overactive Bladder

NCT01848366
COMPLETED NA

Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)

NCT01731470
COMPLETED NA

Autologous Stem Cells for Urinary Incontinence: Single Patient Compassionate Use

NCT01648491
COMPLETED

Pelvic Floor Physical Therapy-Biomarkers Project

NCT01669694
COMPLETED Phase 2

Prospective Trial Comparing Response to Hyperbaric Oxygen Treatment in Patients With Interstitial Cystitis

NCT01479725
COMPLETED NA

Intravesical Liposomes for Ulcerative Cystitis

NCT01083979
COMPLETED Phase 2

CC-10004 For The Treatment Of Vulvodynia

NCT00814632
COMPLETED Phase 2

An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome

NCT00701311
COMPLETED

Urology Database for Outcomes Research

NCT00444730
TERMINATED Phase 2

Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain

NCT00301405
TERMINATED

InterStim Prospective Database

NCT00441935
COMPLETED

Impact Of Sacral Neuromodulation On Urine Markers For Interstitial Cystitis (IC)

NCT00704457
COMPLETED

Urology Database to Evaluate Clinical Information and Improve Patient Care.

NCT00376298
TERMINATED

Prostatectomy Prospective Database

NCT00447616

Phase Distribution

PhaseTrial count
Phase 2 4

Therapeutic Areas

Vulvodynia 1
Interstitial Cystitis 1
Pelvic Pain 1

How the Kenneth Peters, MD early-phase archive is shaped

14 indexed studies, none listed as recruiting (0% open); 11 completed (79%).

Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).

Top condition: Vulvodynia (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Kenneth Peters, MD: archived-pipeline peers nationwide

Peers matched on 14 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Kenneth Peters, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Kenneth Peters, MD3-C Institute for Social DevelopmentAbbott Medical OpticsAbbott RDx CardiometabolicAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA10xBio22nd Century Group23andMe3 Waves Wellness
Kenneth Peters, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Kenneth Peters, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 14 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Kenneth Peters, MD page

14 registered trials is a research-attention snapshot, not an endorsement of Kenneth Peters, MD or any single study.

  • None of Kenneth Peters, MD's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Vulvodynia is the condition Kenneth Peters, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Vulvodynia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Kenneth Peters, MD pipeline card: 14 registered trials from official public datasets.Report a data error.